Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T21:07:55.756Z.
Calculation as of: 2026-10-06T21:07:55.756Z.
Quote observation: 2026-10-06T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a446221ee70341de49d615c46e15f9be625c30a72cedc9ff9e6473dbc59ae23
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
NRx Pharmaceuticals, Inc.
Market Cap
$127.29M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$130.79M
Price/OCF Ratio
4.63
TTM Avg
39.51
3Y Avg
39.66
5Y Avg
39.66
Market Cap
$131.21M
Price/OCF Ratio
102.75
TTM Avg
51.49
3Y Avg
30.98
5Y Avg
26.48
Market Cap
$122.66M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| NRx Pharmaceuticals, Inc. (NRXP) | $127.29M | N/A | N/A | N/A | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.98M | N/A | N/A | N/A | N/A |
| Entera Bio Ltd. (ENTX)vs › | $124.70M | N/A | N/A | N/A | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $124.18M | N/A | N/A | N/A | N/A |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | 4.63 | 39.51 | 39.66 | 39.66 |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | 102.75 | 51.49 | 30.98 | 26.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $122.66M | N/A | N/A | N/A | N/A |
| LifeMD, Inc. (LFMD)vs › | $132.03M | N/A | 20.60 | 44.02 | 44.02 |
| BGM Group Ltd. (BGM)vs › | $122.43M | N/A | N/A | N/A | N/A |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
